SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2008 / Cilt: 56 - Sayı: 3

New approaches in antibiotic therapies in chronic pulmonary diseases

Çocuklarda kronik akciğer hastalıklarının antibiyotik tedavisinde yeni yaklaşımlar

Emine KOCABAŞ
Ümit ÇELİK
Pages
353–363
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review is an argument of antibiotic usage regimens at cystic fibrosis, bronchiectasis and allergic bronchopulmonary aspergillosis which are the most usual chronic lung diseases seen at childhood and adults.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic lung diseases are one of the considerable problems in childhood both for physcians and patients.
📊
Key Findings & Data:Due to early diagnosis of illness and complications; advances at vaccination methods and antibiotic therapies; life period of patients have been prolonged so not only at childhood but at adults, chronic lung diseases seem to be important healthy problem.
💡
Conclusion & Impact:This review is an argument of antibiotic usage regimens at cystic fibrosis, bronchiectasis and allergic bronchopulmonary aspergillosis which are the most usual chronic lung diseases seen at childhood and adults.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic lung diseases are one of the considerable problems in childhood both for physcians and patients. Due to early diagnosis of illness and complications; advances at vaccination methods and antibiotic therapies; life period of patients have been prolonged so not only at childhood but at adults, chronic lung diseases seem to be important healthy problem. One of the most important factors affectting to prognosis of the diseases are concominant infections. This review is an argument of antibiotic usage regimens at cystic fibrosis, bronchiectasis and allergic bronchopulmonary aspergillosis which are the most usual chronic lung diseases seen at childhood and adults.

Özet

Kronik akciğer hastalıkları, çocukluk çağında hem hasta hem de hekim için önemli sağlık sorunlarından biridir. Tanı yöntemlerindeki gelişmeler sonucu, bu hastalıkların erken dönemde tanımlanması, gelişebilecek komplikasyonların erken tanısı, aşılama yöntemlerinde ilerlemeler ve erken antibiyotik tedavileri sonucu hastaların yaşam sürelerindeki uzama, bu hastalıkları sadece çocukların değil, erişkinlerin de önemli bir sağlık sorunu haline getirilmiştir. Hastalığın prognozunu etkileyen en önemli etmenlerden birisi, üzerine eklenen infeksiyonlardır. Bu yazıda; çocuklarda ve erişkinlerde sık görülen kronik akciğer hastalıklarından olan kistik fibrozis, bronşektazi ve allerjik bronkopulmoner aspergillozda antibiyotik kullanım ilkeleri bu konudaki son gelişmeler eşliğinde tartışılmıştır.

🔖

Cite This Article

KOCABAŞ, E., ÇELİK, Ü. (2022). New approaches in antibiotic therapies in chronic pulmonary diseases. Tüberküloz ve Toraks, Cilt: 56 - Sayı: 3, 353–363. https://ajindex.com/articles/618990

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 1989; 245: 1059-65
  2. Slieker MG, Viterwool CS, Sinaasappel M, et al. Birth prevalence and survival in cystic fibrosis: A national cohort study in the Netherlands. Chest 2005; 128: 2309-15
  3. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: Cross sectional study. BMJ 1998; 316: 1771-5
  4. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51
  5. Brennan AL, Geddes DM. Cystic fibrosis. Curr Opin Infect Dis 2002; 15: 175-82
  6. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356-66
  7. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100
  8. Simon RH. Treatment of cystic fibrosis. www.uptodate.com 9. Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413-21
  9. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-29
  10. Bolton CE, Ionescu AA, Evans WD, et al. Altered tissue distribution in adults with cystic fibrosis. Thorax 2003;58: 885-9
  11. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20: 149-60
  12. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis the TOPIC study: A randomised controlled trial. Lancet 2005; 365: 573-8
  13. Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2001; (4): CD002767
  14. Diver JM, Schollaardt T, Rabin HR, et al. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991; 35: 1538-46
  15. Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993; 87: 587-93
  16. Szaff M, Hoiby N, Flensborg EW.